"It is likely that hUCBs can modify this inflammatory response and provide beneficial effects in animal models of AD," said Dr. Tan, who recently completed a study in which the brain-to-blood clearance of AB was demonstrated. Based on the findings of this research, Dr. Tan is developing clinical protocols with Saneron CCEL Therapeutics, Inc. and the USF Health Byrd Alzheimer's Institute.
"Our immediate goal is to move our beneficial findings with cord blood cells into clinical trials for patients with mild to moderate Alzheimer's disease," said Dr. Tan.
This research is part of an ongoing research partnership between USF and Saneron*, Cryo-Cell and Cryopraxis aimed at determining the therapeutic benefits hUCBs present for a variety of neurological diseases, including Parkinson's disease, Lou Gehrig's disease (ALS), Alzheimer's disease, and stroke.
"Our next stage of research is translational, with the goal of bringing these advancements to the patient bedside," said Nicole Kuzmin-Nichols, president and chief operating officer of Saneron. "Saneron is very pleased and excited that our long-standing research partnership with USF has provided to further the technology developed at USF and transferred to Saneron for further development."
When hUCB transplantation was studied in animal models of ALS, also a neurodegenerative disease with an inflammatory component, hUCB transplantation was shown to help regulate the inflammatory response by reducing the number of microglia - brain cells that initiate an inflammatory response. In this case, the benefits of injected hUCBs were dose-related.
"In contrast to when hUCBs were transplanted into animal models of stroke and AD, a considerable number of hUCBs were detected within the spinal cord in animal models of ALS," said Dr. Svitlana Garbuzo
|Contact: David Eve|
Cell Transplantation Center of Excellence for Aging and Brain Repair